Novocure NVCR 深 滬
等待開盤 10-25 09:30:00 美东时间
13.725
-0.195
-1.40%
華盛通- 最 高14.17
- 今 開14.17
- 成交量 63.77万股
- 最 低 13.53
- 昨 收 13.92
- 總市值 15.37亿
- 52周最高 34.13
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 10.87
- 委 比 -34.48%
- 總股本 1.12亿
- 歷史最高 232.76
- 量 比 0.69
- 振 幅 4.60%
- 歷史最低 5.95
- 每 手 1
- 風險率 5.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Novocure To Present Final Results From Phase 3 METIS Trial Of Tumor Treating Fields Therapy For Brain Metastases From NSCLC At 2025 ASTRO
METIS trial achieved its primary endpoint, showing a statistically significant delay in time to intracranial progression in patients receiving TTFields therapy and best supportive care following stereotactic radiation of the metastasesResults from the METIS trial published in the International Journal of Radiation Oncology Biology and Physics
09-30 04:32
Japan's Ministry Of Health, Labour And Welfare Approves Novocure's Optune Lua For Concurrent Use With PD-1/PD-L1 Inhibitors For Adult Patients With Unresectable Advanced/Recurrent Non-small Cell Lung Cancer Who Have Progressed On Or After Platinum-Based Chemotherapy
Optune Lua is a wearable, portable medical device that produces alternating electric fields known as Tumor Treating Fields (TTFields), which are delivered through non-invasive, wearable arrays. TTFields exert physical
09-15 19:03
ImmunityBio rises on data for NK cell therapy, device combo for glioblastoma
All five patients in a trial with recurrent glioblastoma given a combination of ImmunityBio's (NASDAQ:IBRX) natural killer (NK) cell therapy Anktiva and Novocure's (NASDAQ:NVCR) Optune Gio Tumor Treat...
08-26 23:21
最新！10款医疗器械进入创新通道
2025年8月5日，NMPA公布了创新医疗器械特别审查申请审查结果公示（2025年第7号），有10款产品进入创新通道。 1.产品名称：产前胎儿畸形...
08-06 11:56
Top 3 Health Care Stocks That May Explode In July
The most oversold stocks in the health care sector presents an opportunity to b...
07-28 18:52
美股周涨跌榜 | 本周飙升568%！Abivax S.A.新药III期研究成功；CRO股Medpace周涨超43%
本周飙升568%！生物技术公司Abivax S.A.溃疡性结肠炎口服药物III期研究成功；CRO股Medpace周涨超43%，Q2营收和EBITDA均超预期>>
07-26 10:23
Wells Fargo Downgrades NovoCure to Equal-Weight, Lowers Price Target to $14.5
Wells Fargo analyst Larry Biegelsen downgrades NovoCure (NASDAQ:NVCR) from Overweight to Equal-Weight and lowers the price target from $40 to $14.5.
07-25 21:22
NocoCure shares are trading lower. The company reported Q2 financial results.
NocoCure shares are trading lower. The company reported Q2 financial results.
07-24 23:05
Earnings Scheduled For July 24, 2025
Companies Reporting Before The Bell • Deutsche Bank (NYSE:DB) is likely to repo...
07-24 16:32
NovoCure Earnings Preview
NovoCure (NASDAQ:NVCR) is set to give its latest quarterly earnings report on T...
07-24 05:02
